NO20082350L - Piperidin-4-YL-pyridazin-3-ylamin derivat som rask dissosiasjon dopamin 2-reseptor antagonister - Google Patents

Piperidin-4-YL-pyridazin-3-ylamin derivat som rask dissosiasjon dopamin 2-reseptor antagonister

Info

Publication number
NO20082350L
NO20082350L NO20082350A NO20082350A NO20082350L NO 20082350 L NO20082350 L NO 20082350L NO 20082350 A NO20082350 A NO 20082350A NO 20082350 A NO20082350 A NO 20082350A NO 20082350 L NO20082350 L NO 20082350L
Authority
NO
Norway
Prior art keywords
receptor antagonists
dopamine
compounds
pyridazin
piperidin
Prior art date
Application number
NO20082350A
Other languages
English (en)
Inventor
Ludo Edmond Josephine Kennis
Marcel Frans Leopold De Bruyn
Xavier Jean Michel Langlois
Yves Emiel Maria Va Roosbroeck
Gregor James Macdonald
Frans Alfons Maria Van Keybus
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20082350L publication Critical patent/NO20082350L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Den foreliggende oppfinnelsen vedrører forbindelser som er hurtige dissosierende dopamin 2 reseptorantagonister, prosesser for å fremstille disse forbindelsene, farmasøytiske blandinger som består av disse forbindelsene som et aktivt innholdsstoff. Forbindelsene kan benyttes som medisiner til behandling eller forebygging av forstyrrelser i sentralnervesystemet, for eksempel schizofreni, ved å utøve en antipsykotisk effekt uten motoriske bivirkninger.
NO20082350A 2005-10-26 2008-05-26 Piperidin-4-YL-pyridazin-3-ylamin derivat som rask dissosiasjon dopamin 2-reseptor antagonister NO20082350L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05110028 2005-10-26
EP06100209 2006-01-10
EP06101545 2006-02-10
PCT/EP2006/067696 WO2007048779A1 (en) 2005-10-26 2006-10-24 Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists

Publications (1)

Publication Number Publication Date
NO20082350L true NO20082350L (no) 2008-07-01

Family

ID=35734993

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082350A NO20082350L (no) 2005-10-26 2008-05-26 Piperidin-4-YL-pyridazin-3-ylamin derivat som rask dissosiasjon dopamin 2-reseptor antagonister

Country Status (35)

Country Link
US (3) US8940743B2 (no)
EP (1) EP1943242B1 (no)
JP (1) JP5140598B2 (no)
KR (1) KR101351910B1 (no)
CN (1) CN101291925B (no)
AP (1) AP2607A (no)
AR (1) AR058151A1 (no)
AT (1) ATE495167T1 (no)
AU (1) AU2006307930B2 (no)
BR (1) BRPI0617787A2 (no)
CA (1) CA2623160C (no)
CR (1) CR10020A (no)
CY (1) CY1111977T1 (no)
DE (1) DE602006019624D1 (no)
DK (1) DK1943242T3 (no)
EA (1) EA015681B1 (no)
EC (1) ECSP088396A (no)
ES (1) ES2359020T3 (no)
GT (1) GT200800033A (no)
HK (1) HK1124317A1 (no)
HN (1) HN2008000646A (no)
HR (1) HRP20110226T1 (no)
IL (1) IL191016A (no)
JO (1) JO2769B1 (no)
MY (1) MY145609A (no)
NO (1) NO20082350L (no)
NZ (1) NZ566785A (no)
PL (1) PL1943242T3 (no)
PT (1) PT1943242E (no)
RS (1) RS51674B (no)
SI (1) SI1943242T1 (no)
TW (1) TWI399373B (no)
UA (1) UA94058C2 (no)
WO (1) WO2007048779A1 (no)
ZA (1) ZA200803668B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
JO2642B1 (en) * 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
EP2148872A1 (en) * 2007-04-23 2010-02-03 Janssen Pharmaceutica, N.V. Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists
CA2682671C (en) 2007-04-23 2015-11-17 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
US8906921B2 (en) * 2007-04-23 2014-12-09 Janssen Pharmaceutica Nv 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
US8653262B2 (en) 2007-05-31 2014-02-18 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists and uses thereof
MX2011000043A (es) * 2008-07-03 2011-02-22 Janssen Pharmaceutica Nv 6-(1-piperazinil)-piridazinas sustituidas como antagonistas del receptor 5-ht6.
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
WO2010012758A1 (en) * 2008-07-31 2010-02-04 Janssen Pharmaceutica Nv Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
JP2012512834A (ja) 2008-12-19 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症、喘息及びｃｏｐｄの処置のためのｃｃｒ２受容体アンタゴニストとしての環状ピリミジン−４−カルボキサミド
CN102596961B (zh) 2009-10-30 2015-12-02 詹森药业有限公司 咪唑并[1，2-b]哒嗪衍生物及其作为PDE10抑制剂的用途
CN102933579B (zh) 2009-12-17 2015-07-15 贝林格尔.英格海姆国际有限公司 新的ccr2受体拮抗剂及其用途
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
US10604523B2 (en) 2011-06-27 2020-03-31 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
RU2657540C2 (ru) 2012-06-26 2018-06-14 Янссен Фармацевтика Нв Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств
EP2869822B1 (en) 2012-07-09 2016-09-14 Janssen Pharmaceutica, N.V. Inhibitors of phosphodiesterase 10 enzyme
WO2017004537A1 (en) 2015-07-02 2017-01-05 Centrexion Therapeutics Corporation (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
US20180350708A1 (en) * 2017-06-06 2018-12-06 Powertech Technology Inc. Package structure and manufacturing method thereof

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933823A (en) * 1971-03-29 1976-01-20 E. R. Squibb & Sons, Inc. Isoxazolopyridine ketone derivatives
DE2341965C3 (de) * 1973-08-20 1979-01-25 C.H. Boehringer Sohn, 6507 Ingelheim 4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen
US4197304A (en) * 1975-09-23 1980-04-08 Janssen Pharmaceutica N.V. N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides
NO147672C (no) 1975-09-23 1983-05-25 Janssen Pharmaceutica Nv Analogifremgangsmaate for fremstilling av n-aryl-n-(1-l1-4-piperidinyl)-arylacetamider
EG12406A (en) * 1976-08-12 1979-03-31 Janssen Pharmaceutica Nv Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides
DE3218482A1 (de) 1982-05-15 1983-11-17 Bayer Ag, 5090 Leverkusen Substituierte 5-trifluormethyl-1,3,4-thiadiazol-2-yloxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
ES8802151A1 (es) 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
PT93060B (pt) 1989-02-07 1995-12-29 Sanofi Sa Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem
US5461053A (en) * 1989-02-07 1995-10-24 Sanofi Pyridazine derivatives
GB9008850D0 (en) * 1990-04-19 1990-06-13 Janssen Pharmaceutica Nv Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones
GB9216298D0 (en) 1991-08-15 1992-09-16 Ici Plc Piperidine derivatives
EP0737189B1 (en) 1993-12-28 1999-07-28 PHARMACIA & UPJOHN COMPANY Heterocyclic compounds for the treatment of cns and cardiovascular disorders
DE4425145A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung von Thiazol- und Thiadiazolverbindungen
TW406075B (en) * 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5753679A (en) 1995-05-10 1998-05-19 Hoffmann-La Roche Inc. Benzyl-piperidine derivatives
MY116093A (en) * 1996-02-26 2003-11-28 Upjohn Co Azolyl piperazinyl phenyl oxazolidinone antimicrobials
TW504510B (en) * 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
IL133960A0 (en) * 1997-08-15 2001-04-30 Pfizer Prod Inc 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives
KR100261139B1 (ko) 1998-01-16 2000-08-01 황준수 신규한 알릴티오피리다진 유도체 및 그의 제조방법
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
YU64303A (sh) 2001-02-23 2006-05-25 Merck & Co.Inc. N-supstituisani nearil-heterociklični antagonisti nmda/nr2b
EP1443046B1 (en) 2001-10-09 2008-12-17 Kyorin Pharmaceutical Co., Ltd. Novel 4-(2furoyl)aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same
GB0127832D0 (en) 2001-11-20 2002-01-09 Jagotec Ag Method for the preparation of pharmaceutical nanosuspensions
WO2003049736A1 (en) 2001-12-11 2003-06-19 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
CA2474322A1 (en) 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
US20030236259A1 (en) 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
WO2003066604A2 (en) 2002-02-05 2003-08-14 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
DE60334972D1 (de) 2002-02-22 2010-12-30 Pharmacia & Upjohn Co Llc Pyridylsulfon-derivate als 5-ht6 rezeptor liganden
SE0201544D0 (sv) 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
JP3625214B2 (ja) * 2002-09-26 2005-03-02 株式会社マンダム 防腐殺菌剤並びに該防腐殺菌剤を配合した化粧料、医薬品及び食品
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
BRPI0408704A (pt) 2003-03-24 2006-03-07 Hoffmann La Roche benzil-piridazinonas como inibidores de transcriptase reversa
ATE476954T1 (de) 2003-05-07 2010-08-15 Kemira Pigments Oy Zusammensetzungen zur gezielten freisetzung von duftstoffen und aromen
CN100582103C (zh) 2003-05-08 2010-01-20 杏林制药株式会社 作为搔痒治疗药有效的4-(2-呋喃甲酰基)氨基哌啶类化合物
WO2005005779A2 (en) 2003-07-14 2005-01-20 Genesis Mining Technologies (Pty) Ltd Dual retention cutting arrangement
AU2004259263B2 (en) 2003-07-29 2010-12-16 High Point Pharmaceuticals, Llc Pyridazinyl- piperazines and their use as histamine H3 receptor ligands
EP2316827B1 (en) 2003-07-30 2016-01-27 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
JP2007501801A (ja) 2003-08-07 2007-02-01 日本たばこ産業株式会社 ピロロ［１，２−ｂ］ピリダジン誘導体
US7863044B2 (en) 2003-10-24 2011-01-04 Tao Cheng p18 in stem cell manipulations
AR047537A1 (es) 2004-02-10 2006-01-25 Janssen Pharmaceutica Nv Piridazinonaureas como antagonistas de integrinas
JP4627315B2 (ja) 2004-03-23 2011-02-09 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤としてのベンジルピリダジノン誘導体
JP2007534740A (ja) 2004-04-28 2007-11-29 ファイザー・インク バソプレッシンＶ１ａ受容体の阻害剤としての３−ヘテロシクリル−４−フェニル−トリアゾール誘導体
CN101005842A (zh) 2004-05-28 2007-07-25 弗特克斯药品有限公司 蕈毒碱性受体调节剂
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
AR051092A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
EP1805158B1 (en) 2004-10-29 2018-06-27 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of ppar
EP1868652A2 (en) * 2005-04-05 2007-12-26 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Method for shielding functional sites or epitopes on proteins
TW200738676A (en) 2005-06-20 2007-10-16 Schering Corp Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
US7754744B2 (en) 2006-08-15 2010-07-13 Hoffmann-La Roche Inc. Substituted piperidinamines as somatostatin receptor subtype 5 (SSTR5) antagonists
CA2606658A1 (en) * 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
TW200829566A (en) 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
JO2642B1 (en) * 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
CA2682671C (en) * 2007-04-23 2015-11-17 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
US8906921B2 (en) * 2007-04-23 2014-12-09 Janssen Pharmaceutica Nv 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
EP2148872A1 (en) * 2007-04-23 2010-02-03 Janssen Pharmaceutica, N.V. Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists
US8299257B2 (en) * 2007-09-20 2012-10-30 Glaxo Group Limited Compounds which have activity at M1receptor and their uses in medicine
MX2011000043A (es) * 2008-07-03 2011-02-22 Janssen Pharmaceutica Nv 6-(1-piperazinil)-piridazinas sustituidas como antagonistas del receptor 5-ht6.
WO2010012758A1 (en) 2008-07-31 2010-02-04 Janssen Pharmaceutica Nv Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists

Also Published As

Publication number Publication date
TWI399373B (zh) 2013-06-21
CY1111977T1 (el) 2015-11-04
HRP20110226T1 (hr) 2011-05-31
US20080227791A1 (en) 2008-09-18
EA200801184A1 (ru) 2008-08-29
US8940743B2 (en) 2015-01-27
GT200800033A (es) 2009-08-20
EP1943242B1 (en) 2011-01-12
ZA200803668B (en) 2009-09-30
IL191016A (en) 2013-10-31
CA2623160C (en) 2013-10-15
JP5140598B2 (ja) 2013-02-06
PL1943242T3 (pl) 2011-06-30
KR20080067658A (ko) 2008-07-21
KR101351910B1 (ko) 2014-01-16
CA2623160A1 (en) 2007-05-03
MY145609A (en) 2012-03-15
BRPI0617787A2 (pt) 2009-12-01
PT1943242E (pt) 2011-04-06
CN101291925A (zh) 2008-10-22
TW200732321A (en) 2007-09-01
CR10020A (es) 2009-01-16
UA94058C2 (ru) 2011-04-11
ATE495167T1 (de) 2011-01-15
DE602006019624D1 (de) 2011-02-24
EP1943242A1 (en) 2008-07-16
AP2607A (en) 2013-03-05
CN101291925B (zh) 2013-04-10
AU2006307930A1 (en) 2007-05-03
HN2008000646A (es) 2011-02-16
RS51674B (en) 2011-10-31
AP2008004441A0 (en) 2008-04-30
DK1943242T3 (da) 2011-04-26
US20170022181A1 (en) 2017-01-26
WO2007048779A1 (en) 2007-05-03
US9751860B2 (en) 2017-09-05
JO2769B1 (en) 2014-03-15
AU2006307930B2 (en) 2011-10-06
AR058151A1 (es) 2008-01-23
SI1943242T1 (sl) 2011-05-31
ECSP088396A (es) 2008-05-30
HK1124317A1 (en) 2009-07-10
ES2359020T3 (es) 2011-05-17
US9468640B2 (en) 2016-10-18
NZ566785A (en) 2010-03-26
EA015681B1 (ru) 2011-10-31
JP2009514815A (ja) 2009-04-09
US20150141432A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
NO20082350L (no) Piperidin-4-YL-pyridazin-3-ylamin derivat som rask dissosiasjon dopamin 2-reseptor antagonister
NO20090267L (no) Substituerte N-fenylmetyl-5-okso-prolin-2-amider som P2X7-receptorantagonister og deres anvendelse
JO2849B1 (en) Dopamine 2 receptor antagonists are rapidly hydrolyzed
WO2013153479A3 (en) Indole and indazole compounds that activate ampk
DE602008005771D1 (de) Disubstituierte alkyl-8-azabicycloä3.2.1üoktan-verbindungen als mu-opioid-rezeptorantagonisten
WO2009097287A9 (en) Compounds and compositions as kinase inhibitors
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
WO2008132139A3 (en) New heterocyclic derivatives useful for the treatment of cns disorders
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
WO2008112159A3 (en) Monocyclic anilide spirolactam cgrp receptor antagonists
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
MX2009011415A (es) Derivados de 4-alcoxipiridazina como antagonistas del receptor de dopamina 2 de rapida disociacion.
WO2006120478A3 (en) Quinoline derivatives as neurokinin receptor antagonists
NO20084007L (no) Spirokondenserte piperidiner som modulatorer av muskarinreseptorer
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.
NO20092574L (no) Piperidinylamino-pyridaziner og deres anvendelse som raskt dissosierende dopamin-2-reseptor-antagonister
NO20091052L (no) Diaryleterderivater og anvendelser derav
EA201170256A1 (ru) Пиперазин-1-илтрифторметилзамещенные пиридины в качестве быстро диссоциирующихся антагонистов d2 рецепторов дофамина
MX2007004661A (es) Derivados de 1-(hetero)aril-3-amino-pirrolidina para usarse como antagonistas del receptor mglur3.
MX2009011414A (es) Derivados de piridina como antagonistas del receptor de dopamina 2 de disociacion rapida.
WO2009076408A3 (en) 3 -carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists
NO20091832L (no) Indoler som virker via reseptorantagonister
DE602007004327D1 (de) Einen azepin-kern enthaltende antagonisten des histaminrezeptors
BRPI0606783A2 (pt) derivados de imidazol

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application